11:13 AM EDT, 07/29/2024 (MT Newswires) -- Ventyx Biosciences ( VTYX ) shares fell 24% in recent Monday trading after the company said the phase 2 trial of its VTX958 for participants with moderately to severely active Crohn's disease failed to meet its primary endpoint.

The company said Monday the trial didn't meet its primary endpoint of change in mean Crohn's disease activity index score from baseline to week 12 after to a higher-than-expected placebo response.

Ventyx plans to analyze the trial data further but doesn't expect to conduct additional clinical trials of VTX958.

Price: 2.24, Change: -0.71, Percent Change: -24.10